Therapeutic Advances in Heart failure

Costs of providing a particular medical service can be measured, but it is more difficult to assess whether the service provides good value for the money spent. Extensive cost-effectiveness studies have been conducted on many important cardiovascular therapies:

  • β-blockers and diuretics for multiple CVD outcomes, mortality, and prevention of recurrent myocardial infarction (MI);
  • Statins for both primary and secondary prevention of CVD;
  • Enalapril for prevention and treatment of congestive heart failure;
  • Tissue plasminogen activator treatment of acute MI;
  • Coronary artery bypass graft for left main, single-, and 2-vessel coronary artery disease, or severe angina;
  • Physician counselling for smoking; and
  • Radiofrequency ablation therapy for Wolff-Parkinson-White syndrome.
  • Anticoagulation Therapy and Thrombosis Prevention
  • Aortic Stenosis and TAVR

 

    Related Conference of Therapeutic Advances in Heart failure

    October 20-21, 2026

    15th World Heart Congress

    London, UK
    November 09-10, 2026

    7th Annual Summit on Cardiology and Heart Diseases

    Paris, France
    November 16-17, 2026

    8th World Heart Congress

    Tokyo, Japan
    November 23-24, 2026

    40th World Congress on Heart Diseases

    Toronto, Canada
    November 25-26, 2026

    33rd World Heartcare Summit

    Paris, France
    January 26-27, 2027

    12th International Heart Conference

    Dubai, UAE
    March 18-19, 2027

    16th World Heart Congress

    Paris, France
    May 13-14, 2027

    10th Annual Heart Rhythm Conference

    Rome, Italy
    June 17-18, 2027

    10th World Heart and Brain Conference

    London, UK
    June 21-22, 2027

    8th European Summit on Cardiology Research

    Zurich, Switzerland

    Therapeutic Advances in Heart failure Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in